FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and aims at preventing or treating dry eye syndrome. For prevention or treatment of dry eye syndrome, a pharmaceutical composition containing sulglycotide or its pharmaceutically acceptable salt as an active ingredient is used. Said composition has a dosage form for instillation into eyes.
EFFECT: using the invention enables considerably increasing the tear production, improving the corneal surface irregularities, increasing the density of the conjunctival beaker-shaped cells and reducing the inflammatory cytokines on the eye surface and the lachrymal gland.
7 cl, 2 tbl, 6 dwg, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GEL-LIKE ARTIFICIAL TEARS WITH ANTISEPTIC AND REPARATIVE ACTION | 2018 |
|
RU2679319C1 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION AND METHODS OF ITS PREPARATION AND USE | 2019 |
|
RU2812316C2 |
| ORAL PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF "DRY EYE" SYNDROME CONTAINING REBAMIPID OR ITS PRECURSOR | 2014 |
|
RU2632107C2 |
| PHARMACEUTICAL COMPOSITION FOR INTEGRATED TREATMENT OF OCULAR SURFACE DISEASES IN PATIENTS SUFFERING PRIMARY OPEN-ANGLE GLAUCOMA | 2011 |
|
RU2460517C1 |
| PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | 2019 |
|
RU2819399C2 |
| OPHTHALMIC HUMIDIFIER AND METHOD FOR PREPARATION THEREOF | 2024 |
|
RU2839755C1 |
| OPHTHALMIC COMPOSITION CONTAINING CYCLOSPORINE AND TREHALOSE | 2015 |
|
RU2700927C2 |
| COMPOSITION FOR INTEGRATED TREATMENT OF PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR SURFACE DISEASES | 2011 |
|
RU2464985C1 |
| COMPOSITION FOR INTEGRATED TREATMENT OF PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR SURFACE DISEASES | 2013 |
|
RU2517033C1 |
| COMPOSITION FOR EFFECTIVE LIPID DELIVERY TO HUMAN TEAR FILM USING SALT-SENSITIVE EMULSION SYSTEM | 2012 |
|
RU2772357C2 |
